B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) yesterday and set a price target of $6.00. The company’s shares closed yesterday at $2.19.
According to TipRanks, Mamtani is an analyst with an average return of -22.5% and a 23.61% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Madrigal Pharmaceuticals, and CymaBay Therapeutics.
Currently, the analyst consensus on Trevi Therapeutics is a Moderate Buy with an average price target of $6.50.
See today’s best-performing stocks on TipRanks >>
TRVI market cap is currently $144.3M and has a P/E ratio of -7.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
Read More on TRVI:
